A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE SRL
Via Sette Santi, 1 50131 - Firenze (Firenze) Phone +39 055 56801 Fax +39 055 582771
Via Sette Santi, 1 50131 - Firenze (Firenze) Telefono +39 055 56801 Fax +39 055 582771
Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.
Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.
What does it really make Menarini unique? The diversity and authenticity of our key resource - the People. Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.
Menarini employees make all the difference, every day.
Ogni giorno mettiamo in pratica i nostri valori. 4 valori, che hanno dato vita a Menarini e ne hanno forgiato la storia.
Menarini investe continuamente nella scienza e nelle tecnologie all'avanguardia per lo sviluppo di una pipeline di nuovi prodotti che facciano la differenza nella vita dei pazienti affetti da gravi patologie.
Menarini è un’azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un’eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development è impegnato a valutare ed esplorare nuove opportunità innovative.
Dalla distribuzione di pasti e medicinali, dai kit per andare a scuola alla promozione dello sport all'aiuto per le donne in gravidanza: essere responsabili, per noi di Menarini, significa tradurre le buone intenzioni in sforzi concreti. Aiutando gli altri diamo il nostro contributo a migliorare il mondo che ci circonda, a partire da noi.
Che cosa rende davvero Menarini unica? La diversità ed autenticità del nostro valore più importante - le Persone. La nostra diversità culturale ci aiuta a guidare l'innovazione, ad adattarci ai cambiamenti di mercato, ad affrontare le sfide, ad ispirare idee e a promuovere la nostra crescita.
Chi lavora in Menarini fa la differenza, ogni giorno.
2018 - 9 - 19
Pomezia, September 19, 2018 – Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing that pre-treatment with 5-Azacytidine and Decitabine enhances the Antibody-dependent cellular cytotoxicity (ADCC) of the clinical candidate MEN1112/OBT357 on several Acute Myeloid Leukemia (AML) cell lines.
MEN1112/OBT357 is a monoclonal antibody targeting CD157, a myeloid marker present on leukemia cells. Menarini has partnered with Oxford BioTherapeutics to conduct the development of the compound. A comprehensive work of preclinical characterization has been already fulfilled and MEN1112/OBT357 is currently in phase I clinical trial for the treatment of patients with relapsed/refractory (R/R) Acute Myeloid Leukemia (AML).
The experimental results that will be presented strongly suggest that pre-treatment with 5-Azacytidine and Decitabine enhances the cell killing activity of MEN1112/OBT357 on SKNO-1, HL60 and K052 cell lines.
“We observed a statistically significant synergism between different doses of MEN1112/OBT357 and 5-Azacytidine and Decitabine on a number of AML cell lines” said Monica Binaschi, PhD, Director of the Preclinical and Translational Oncology Department of Menarini Ricerche, “These results seem to confirm the immune-modulatory role of 5-Azacytidine and Decitabine, which may increase the sensitivity of leukemic cells to MEN1112/OBT357. These new findings suggest that pretreatment with these two agents could promote and enhance tumor cell killing activity by MEN1112/OBT357, and provide a strong rationale for evaluating these combinations in clinical trial.”
The poster “The ADCC-mediated activity of the de-fucosylated monoclonal antibody MEN1112/OBT357 is increased by pre-treatment with 5-Azacytidine and Decitabine in acute myeloid leukemia cell lines” will be presented on September 20th, 2018, 12.00-13.00 and on September 21st, 2018, 12.00-13.00.
Discover our stories from all over the world
Menarini � un�azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un�eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development � impegnato a valutare ed esplorare nuove opportunità innovative.
Scopri le nostre storie da tutto il mondo